Key Points
- CEO James Mackin sold 30,921 shares on Dec. 2 at an average price of $45.56 for proceeds of about $1.41M, trimming his stake by 3.72% to 800,993 shares (SEC filing).
- Artivion beat Q3 estimates, reporting $0.16 EPS vs. $0.14 expected and revenue of $113.39M (up 18.9% YoY), though the company still shows a negative net margin (-2.16%).
- Analyst sentiment is largely positive with multiple price-target increases (range raised into the $47–$58 area) and an average target of about $49.11, with most firms rating the stock a Buy or Outperform.
Artivion, Inc. (NYSE:AORT - Get Free Report) CEO James Mackin sold 30,921 shares of the company's stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $45.56, for a total value of $1,408,760.76. Following the sale, the chief executive officer directly owned 800,993 shares in the company, valued at $36,493,241.08. This trade represents a 3.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Artivion Trading Up 0.5%
Shares of AORT opened at $45.59 on Thursday. The company's fifty day moving average is $43.86 and its 200 day moving average is $37.95. Artivion, Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $48.04. The stock has a market capitalization of $2.16 billion, a PE ratio of -189.95 and a beta of 1.60. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.88 and a current ratio of 3.93.
Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.14 by $0.02. Artivion had a negative net margin of 2.16% and a positive return on equity of 5.98%. The business had revenue of $113.39 million during the quarter, compared to analyst estimates of $110.71 million. The business's revenue for the quarter was up 18.9% compared to the same quarter last year. Sell-side analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.
Analysts Set New Price Targets
AORT has been the subject of several analyst reports. JMP Securities raised their price objective on Artivion from $42.00 to $47.00 and gave the company a "market outperform" rating in a research note on Friday, October 10th. LADENBURG THALM/SH SH lowered shares of Artivion from a "buy" rating to a "neutral" rating and lifted their price objective for the stock from $32.00 to $38.80 in a research note on Wednesday, August 13th. Oppenheimer reissued an "outperform" rating and issued a $50.00 target price on shares of Artivion in a research note on Friday, November 7th. Canaccord Genuity Group raised their target price on shares of Artivion from $50.00 to $51.00 and gave the stock a "buy" rating in a report on Friday, November 7th. Finally, Needham & Company LLC upped their price target on shares of Artivion from $50.00 to $58.00 and gave the company a "buy" rating in a report on Friday, November 7th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Artivion has an average rating of "Moderate Buy" and an average price target of $49.11.
Get Our Latest Stock Report on Artivion
Institutional Investors Weigh In On Artivion
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Artivion by 18.9% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,358 shares of the company's stock worth $353,000 after acquiring an additional 2,285 shares in the last quarter. Natixis Advisors LLC boosted its holdings in shares of Artivion by 16.4% in the first quarter. Natixis Advisors LLC now owns 12,615 shares of the company's stock valued at $310,000 after purchasing an additional 1,777 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Artivion by 5.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 376,052 shares of the company's stock valued at $9,243,000 after purchasing an additional 17,860 shares during the period. Invesco Ltd. grew its stake in Artivion by 27.9% in the first quarter. Invesco Ltd. now owns 341,656 shares of the company's stock worth $8,398,000 after purchasing an additional 74,589 shares in the last quarter. Finally, Nuveen LLC purchased a new position in Artivion during the 1st quarter worth $2,653,000. Institutional investors own 86.37% of the company's stock.
Artivion Company Profile
(
Get Free Report)
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
